Sarcoidosis of the central nervous system: Safety and efficacy of treatment, and experience of biological therapies

Desmond P Kidd,Desmond P. Kidd

DOI: https://doi.org/10.1016/j.clineuro.2020.105811

IF: 1.885

2020-07-01

Clinical Neurology and Neurosurgery

Abstract:Neurosarcoidosis is very rare and the natural history under-researched.The optimum treatment and treatment outcome has been studied and the results presented.A treatment paradigm may be established.Further research into optimization of treatment in the disease may be established.Neurological complications of sarcoidosis are uncommon and the natural history and optimal treatments under-researched. With the advent of biological therapies, it is important to define the clinical characteristics and immunopathology of the disease.Patients and methods: Patients referred to and treated within the Centre for Neurosarcoidosis over a 15 year period who had biopsy proven "highly probable" disease of the central nervous system were studied prospectively.Corticosteroids were used effectively in all patients, immunosuppression in 79% and TNFα antagonists in 23%. Treatment with steroids alone inevitably led to relapse, and low dose immunosuppression was ineffective in those with severe forms of the disease. Use of biological therapies substantially improved outcome.Patients with cranial neuropathy had an excellent outcome. Those with pachymeningitis had marked radiological abnormalities but less disablement. Those with leptomeningitis had an invasive, destructive disease which responded well to treatment but with residual neurological impairments. Treatment was required for many years, but the risk of relapse following treatment withdrawal was low. Infective complications arose in six. There were two deaths, neither directly related to the neurological disease, nor its treatment.This prospective study of the natural history and treatment response in neurosarcoidosis provides evidence that the use of high dose immunosuppression and early and prolonged use of biological therapies is associated with greatly improved outcomes and lower mortality. The data may be used to plan further studies and treatment trials, and provide class IV evidence for the effectiveness of biological agents in the treatment of Neurosarcoidosis.

surgery,clinical neurology